Sociodemographic and Biomedical Correlates of Developmental Delay in 2-and 4-Year-Olds with Sickle Cell Disease

被引:6
|
作者
Schatz, Jeffrey [1 ]
Reinman, Laura [1 ]
Bills, Sarah E. [1 ]
Johnston, Julia D. [1 ]
机构
[1] Univ South Carolina, Dept Psychol, Columbia, SC 29208 USA
来源
基金
美国国家卫生研究院;
关键词
sickle cell disease; child development; preschool children; neurodevelopmental disorders; SILENT CEREBRAL INFARCTS; YOUNG-CHILDREN; TODDLERS; RISK; ABNORMALITIES; INFANTS; BRAIN;
D O I
10.1097/DBP.0000000000001011
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Background: Developmental delay occurs frequently in sickle cell disease (SCD). Psychosocial and biomedical factors contribute to delays, but most studies have not examined the timing of risk factors and developmental delay. We examined sociodemographic and biomedical factors to evaluate whether risks of developmental delay differed across 2 developmental periods. Methods: We examined Ages and Stages Questionnaire, second edition (ASQ-2), outcomes in 2-year-olds (n = 100) and 4-year-olds (n = 101) with SCD. ASQ-2 data were obtained from routine developmental screenings administered as part of health care between 2009 and 2016 at a single hematology clinic. Medical record reviews were used to identify sociodemographic and biomedical factors associated with positive screenings for developmental delay. Results: Two-year-olds with positive ASQ-2 screenings (n = 32; 32%) were less likely to have private health insurance or to have been in formal daycare and more likely to have a severe SCD genotype. Four-year-olds with positive screenings (n = 40; 40%) were more likely to have a severe SCD genotype or an abnormal transcranial Doppler ultrasound (TCD) examination indicating high stroke risk. The strength of the association between positive screenings and insurance status, severe genotypes, and TCD examinations differed across the 2 age groups. Domain-level outcomes on the ASQ-2 also differed across the 2 age groups. Conclusion: The cross-sectional data indicate biomedical and psychosocial risks are related to developmental delay, but the association with specific risk factors differs across age.
引用
收藏
页码:224 / 232
页数:9
相关论文
共 50 条
  • [41] INTERIM SAFETY AND EFFICACY OF VOXELOTOR IN CHILDREN AGED 2 to <4 YEARS WITH SICKLE CELL DISEASE
    Fuh, Beng
    Inati, Adlette
    Inusa, Baba
    Abboud, Miguel
    Norris, Cynthia
    Kalpatthi, Ramasubramanian
    Telfer, Paul
    Trompeter, Sara
    Dixon, Sandy
    Enriquez, Aimee
    Akhlaghi, Fatemeh
    Smith-Whitley, Kim
    Brown, Clark
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S163 - S164
  • [42] MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease
    Demers, Melanie
    Sturtevant, Sarah
    Guertin, Kevin R.
    Gupta, Dipti
    Desai, Kunal
    Vieira, Benjamin F.
    Li, Wenjing
    Hicks, Alexandra
    Ismail, Ayman
    Goncalves, Bronner P.
    Di Caprio, Giuseppe
    Schonbrun, Ethan
    Hansen, Scott
    Musayev, Faik N.
    Safo, Martin K.
    Wood, David K.
    Higgins, John M.
    Light, David R.
    BLOOD ADVANCES, 2021, 5 (05) : 1388 - 1402
  • [43] COUNSELING FOR PRENATAL-DIAGNOSIS OF SICKLE-CELL DISEASE AND BETA-THALASSEMIA MAJOR - A 4 YEAR EXPERIENCE
    ANIONWU, EN
    PATEL, N
    KANJI, G
    RENGES, H
    BROZOVIC, M
    JOURNAL OF MEDICAL GENETICS, 1988, 25 (11) : 769 - 772
  • [44] Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2-to 4-Year-Olds
    van Heusden, Alexander
    Rivero-Arias, Oliver
    Herdman, Michael
    Hiscock, Harriet
    Devlin, Nancy
    Dalziel, Kim
    PHARMACOECONOMICS, 2024, 42 (SUPPL 1) : 129 - 145
  • [45] MetAP2 Inhibition Modifies Hemoglobin S (HbS) to Delay Polymerization and Improve Blood Flow in Sickle Cell Disease
    Demers, Melanie
    Sturtevant, Sarah
    Guertin, Kevin
    Gupta, Dipti
    Desai, Kunal
    Vieira, Benjamin
    Hicks, Alexandra
    Ismail, Ayman
    Nakamura, Yukio
    Goncalves, Bronner
    Di Caprio, Giuseppe
    Schonbrun, Ethan
    Hansen, Scott
    Safo, Martin K.
    Wood, David K.
    Higgins, John M.
    Light, David R.
    BLOOD, 2019, 134
  • [46] 4 YEAR COST-ANALYSIS OF AUTOMATED RED CELL EXCHANGE TRANSFUSION FOR MANAGEMENT OF RECURRENT PAINFUL CRISES IN ADULT PATIENTS WITH SICKLE CELL DISEASE
    Tsitsikas, D. A.
    Ekong, A.
    Berg, L.
    Sirigireddy, B.
    Lewis, N.
    Amos, R. J.
    HAEMATOLOGICA, 2016, 101 : 612 - 613
  • [47] EFFECTS OF ALPHA-THALASSEMIA-2 ON THE DEVELOPMENTAL-CHANGES OF HEMATOLOGICAL VALUES IN CHILDREN WITH SICKLE-CELL DISEASE FROM GEORGIA
    FELICE, AE
    MCKIE, KM
    CLEEK, MP
    MARINO, EM
    KUTLAR, A
    MCKIE, VC
    AMERICAN JOURNAL OF HEMATOLOGY, 1987, 25 (04) : 389 - 400
  • [48] Maternally-transmitted MECP2 gene deletion in a 4-year-old boy with cognitive impairment and developmental delay.
    Bottani, A
    Dayer, A
    Cruzado, D
    Haenggeli, CA
    Antonarakis, SE
    Morris, MA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 632 - 632
  • [49] Analysis of Fetal Hemoglobin Expression within Humanized Sickle Cell Disease Mice Overexpressing the TR2/4 Transgene
    Campbell, Andrew
    Tanabe, Osamu
    Urbonya, Rebekah
    Mathias, Andrea
    Shi, Lihong
    Bonsu, Kwaku Osei
    Douglas, Rhonda
    Halford, Brittne
    Cross, Tamika
    Harrow, David
    Giacherio, Donald
    Engel, James D.
    BLOOD, 2010, 116 (21) : 680 - 681
  • [50] Differential Expression of TLR-2 and CTLA-4 between Alloimmunized and Non-Alloimmunized Individuals with Sickle Cell Disease
    Oliveira, Valeria B.
    Conrado, Marina
    Dezan, Marcia R.
    Rocha, Vanderson
    Mendrone-Junior, Alfredo
    Dinardo, Carla
    TRANSFUSION, 2020, 60 : 145A - 146A